Australian Governments to Streamline Access to Medical Cannabis

PUF Ventures Inc. (“PUF” or the “Company”) (CSE:PUF) (Frankfurt:PU3) (OTCPK:PUFXF), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce its full support of the Council of Australian Governments and their recent decision to significantly reduce the wait time for medical cannabis patients. The Council, made up of leaders from all states and territories of Australia, agreed to a national policy which will reduce the wait time for patients to access medical cannabis from months to days.

“Patient access to medical cannabis is an important issue and we applaud the governments of Australia for reducing the wait times to access these important prescriptions,” said Derek Ivany, President and CEO of PUF Ventures Inc. “As we embark on building the largest state-of-the-art medical cannabis greenhouse in the southern hemisphere, we are encouraged to see regulators embrace the benefits of medical cannabis. The health and wellness benefits of cannabis are irrefutable and easing the pain and suffering of patients is a priority. We will continue to work with local governments and academia to make Solaris Nutraceutical’s 1.2 million sq. ft. high-tech, ultra efficient greenhouse a reality.”

Currently, medical cannabis patients in Australia must wait for months to receive separate approvals from both federal and state regulators. The new national policy calls for a significantly streamlined process through the Therapeutic Goods Administration. The single approval system has been tested in New South Wales and has reduced the wait time for a cannabis prescription from two months to two days.

Through a partnership in Solaris Nutraceuticals, PUF and MYM Nutraceuticals Inc. (CSE: MYM) are advancing the science of medical cannabis in Australia. Solaris has submitted applications and plans with Australia’s Office of Drug Control to build a 1.2 million square-foot greenhouse facility with cannabis production space and a medical research center in the Northern Rivers Region of New South Wales. The facility will deliver environmentally friendly, sun grown medicinal grade cannabis and develop medicines and treatments for pain management and other medical conditions. Solaris has also recently teamed up with Southern Cross University to develop hemp and medicinal cannabis products that will enhance animal and human health. For more information, visit

About PUF Ventures Inc.

PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., an advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit:


Derek Ivany
President & CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.


For further information: PUF Ventures Inc., E: [email protected], T: (800) 783-6056

Click here to connect with PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF) for an Investor Presentation.

The post Australian Governments to Streamline Access to Medical Cannabis appeared first on Investing News Network.


Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Accessibility Tools